23.05.2013,
in
Communications of the companies
Helsinn – Cergas Bocconi
Insieme per l’innovazione tecnologica a supporto della continuità di cura oncologica
16.05.2013,
in
Communications of the companies
Helsinn Group and Eisai Inc.
Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
16.05.2013,
in
Communications of the companies
Nuovo accordo di collaborazione tra Helsinn e Vifor Pharma
Helsinn Healthcare, la multinazionale di Lugano/Pambio-Noranco concede in licenza alla società Vifor Pharma i diritti di vendita del suo nuovo farmaco in sviluppo, netupitant-palonosetron in combinazione fissa, per i mercati di Svizzera, Francia, Spagna, Portogallo, Olanda, Belgio e Lussemburgo
19.02.2013,
in
Communications of the companies
NEWSOur new plant for CHO based mAb or Recombinant Protein manufacturing is ready for the qualification phase
Cerbios-Pharma SA (from now on “Cerbios”) is proud to announce that the construction phase for our new Biotechnology plant is almost concluded
22.10.2012,
in
Communications of the companies
Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin
a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
25.09.2012,
in
Communications of the companies
HELSINN GROUP, SWITZERLAND ANNOUNCES A LICENSE AGREEMENT FOR NETUPITANT
PALONOSETRON FIXED DOSE COMBINATION WITH CJ CHEILJEDANG, SOUTH KOREA FOR KOREA
25.09.2012,
in
Communications of the companies
HELSINN GRANTS TO DARA EXCLUSIVE U.S. COMMERCIAL RIGHTS TO GELCLAIR®
AN FDA-CLEARED ORAL GEL FOR THE TREATMENT OF ORAL MUCOSITIS
25.09.2012,
in
Communications of the companies
